The first case of alloantibody against human platelet antigen‐15b in Japan: possible alloimmunization by a hydatidiform mole

Matsuhashi, Mika; Tsuno, Nelson H.; Kawabata, Michiru; Yokoyama, Takahiro; Tazaki, Yukiko; Takashima, Takeshi; Oda, Hidetaka; Kuroda, Y; Nagayoshi, Yuji; Morita, Shôji; Shibata, Yoichi; Takahashi, Koki

doi:10.1111/j.1537-2995.2009.02537.x

Cited by 11 publications

(15 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical and experimental data of 635 cases of NAITP (71), PTR (562) and PTP (2), diagnosed and studied by Asian platelet immunology laboratories, were reviewed from the literature by searching the PubMed database and Chinese BioMedical (CBM) from 1989 to 2013. Of 635 cases, 168 were Japanese patients in Japan, 159 were Chinese patients in China, 33 were in India, 24 were Chinese patients in Taiwan, five were in South Korea, 241 were in Thailand, two were in Kuwait, and one case each from Oman, Lebanon and Palestine.…”

Section: Characteristics Of Clinically Relevant Platelet Antibodies Imentioning

confidence: 99%

Detection of clinically relevant platelet antibodies in the Asian population

Wu¹

2014

ISBT Science Series

View full text Add to dashboard Cite

Background The detection and identification of the clinically relevant platelet antibodies are important for the diagnosis and management of the affected patients with immune thrombocytopenia.Aims The aim of this study was to investigate the characteristic of clinically relevant platelet antibodies in the Asian population, and to evaluate the ability of platelet immunology laboratories in Asia to detect and identify these platelet antibodies.Methods Total of 635 cases that were diagnosed and studied as NAITP, PTR and PTP by Asian platelet laboratories were reviewed for the clinical and experimental data from the publications.Results Except the anti-HLA and unknown-specificity antibody, the most frequently identified platelet antibody was anti-CD36 (18/635, 18Á35%), and then anti-HPA-3 and anti-HPA-4 (each 5/635, 0Á78%), and anti-HPA-5 (4/635, 0Á62%). Only two cases of anti-HPA-1 antibodies (2/635, 0Á31%) were reported. In 274 cases, including four cases contained anti-HLA antibody, the laboratories could not identify the specificity of platelet antibodies. The methods of detection and identification of antiplatelet antibody, such as monoclonal antibody immobilization of platelet antigens (MAIPA), mixed passive hemagglutination assay (MPHA), platelet immunofluorescence test (PIFT), modified antigen-capture ELISA (MACE) and solid-phase red-cell adherence (SPAA), have been used in Asian laboratories.Conclusion With an increasingly heterogeneous patient population in Asia, diagnostic laboratories should be aware of the ethnic origin of a particular patient to consider the possibility of immunization to antigens. The most important clinical relevant platelet antibodies implicated in immune-mediated thrombocytopenia among the Asian population are anti-CD36, then anti-HPA-3, anti-HPA-4 and others.

show abstract

Section: Characteristics Of Clinically Relevant Platelet Antibodies Imentioning

confidence: 99%

Detection of clinically relevant platelet antibodies in the Asian population

Wu¹

2014

ISBT Science Series

View full text Add to dashboard Cite

show abstract

“…Subsequently, anti-HPA antibody and anti-HLA antibody detections were performed with a mixed passive hemagglutination (MPHA) test and immunocomplex capture fluorescence analysis (ICFA), as described previously (Table 1). [11][12][13] Fetomaternal incompatible HPA and HLA genotypes were HPA-5b,…”

Section: Introductionmentioning

confidence: 98%

“…This severe thrombocytopenia was associated with maternal anti‐HPA‐5b, anti‐HLA‐A31, and anti‐HLA‐B55. Thus we report a unique case of severe FNAIT in a neonate born from a mother with both HPA and HLA alloantibodies of three specificities …”

Section: Introductionmentioning

confidence: 99%

“…Thus we report a unique case of severe FNAIT in a neonate born from a mother with both HPA and HLA alloantibodies of three specificities. [8][9][10][11] The platelet-associated immunoglobulin measured as a screening test at admission revealed levels as high as 800U, which led us to suspect FNAIT. 3,4 Informatively, the platelet counts of the mother at 3 months before and the second day of the delivery were 187 × 10 9 /L and 151 × 10 9 /L, respectively.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Marked thrombocytopenia in a neonate is associated with anti‐HPA‐5b, anti‐HLA‐A31, and anti‐HLA‐B55 antibodies

Okubo

Nishida

Watanabe

et al. 2018

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

Maternal antibodies against human platelet antigen (HPA) and/or human leukocyte antigen (HLA) cause fetal and neonatal alloimmune thrombocytopenia (FNAIT) in 0.09‐0.15% of live births. Severe cases account for 5‐31% and the frequency of multiple kinds of alloantibodies is 6.9‐9% of FNAIT. We present a case of severe FNAIT associated with anti‐HPA‐5b, anti‐HLA‐A31, and anti‐HLA‐B55 antibodies, successfully treated with immunoglobulin and platelet transfusion. The anti‐HLA‐B55 antibody was detected in the newborn's serum, but disappeared on the 20th day, which was followed by an increase of the platelet count. These findings suggested the potential involvement of an anti‐HLA antibody in the pathogenesis of FNAIT.

show abstract

“…Rapid and sensitive detection of HPA alloantibodies is important for good clinical care; thus, several assays have been developed to detect HPA alloantibodies. Of these, mixed‐passive haemagglutination (MPHA) is a classical, simple method using wells coated with intact platelets or its lysate to detect HPA alloantibodies and is the most applied method in Japan . While MPHA can be used to easily detect alloantibodies without equipment such as a microplate reader or the Luminex system, the coexistence of class I human leucocyte antigen (HLA) alloantibodies occasionally occludes HPA alloantibody detection.…”

Section: Introductionmentioning

confidence: 99%

A novel simple assay system for the detection of human platelet antigen 15 (HPA‐15) alloantibodies based on three techniques: an HPA‐15 expressing cell line, a monoclonal antibody‐specific antigen‐capture method and mixed‐passive haemagglutination

et al. 2019

View full text Add to dashboard Cite

Background and objectives To detect HPA‐15 alloantibodies, we previously developed a human platelet antigen 15 (HPA‐15)‐expressing cell line‐based modified rapid monoclonal antibody immobilization of platelet antigen (CL‐MR‐MAIPA) assay. In this study, the protocol was modified for easier performance by introducing the mixed‐passive haemagglutination (MPHA) principle. Material and methods In total, 20 samples that tested negative for HPA alloantibodies and eight that tested positive for HPA‐15 alloantibodies (two and six positive for HPA‐15a and HPA‐15b antibodies, respectively) by CL‐MR‐MAIPA assay were used in this study. HPA‐15 cell lines were incubated with serum/plasma and then solubilized. The lysate was transferred to a round‐bottom well, which was coated with anti‐human CD109 monoclonal antibodies. After incubation and repeated washings, sheep red blood cells, coated with anti‐human IgG, were added to the wells. Haemagglutination was assessed the next day. Results The proposed cell line‐based immune complex capture‐dependent mixed‐passive haemagglutination (CL‐IC‐MPHA) assay consisted of four steps, but required only 2 h to perform, except for overnight incubation for haemagglutination. Two HPA‐15a alloantibody samples were reactive only for HPA‐15a cells, and six HPA‐15b alloantibody samples were reactive only for HPA‐15b cells with the CL‐IC‐MPHA assay. The 20 samples that tested negative for HPA alloantibodies did not react with HPA‐15a or HPA‐15b cells. These data indicated that the CL‐IC‐MPHA assay was highly specific and sensitive. Unfortunately, the CL‐IC‐MPHA assay's analytic sensitivity was twofold to eightfold lower than that of the CL‐MR‐MAIPA assay. Conclusion A novel, easy‐to‐perform protocol was successfully developed to detect HPA‐15 alloantibodies with high specificity and sensitivity.

show abstract

The first case of alloantibody against human platelet antigen‐15b in Japan: possible alloimmunization by a hydatidiform mole

Cited by 11 publications

References 25 publications

Detection of clinically relevant platelet antibodies in the Asian population

Detection of clinically relevant platelet antibodies in the Asian population

Marked thrombocytopenia in a neonate is associated with anti‐HPA‐5b, anti‐HLA‐A31, and anti‐HLA‐B55 antibodies

A novel simple assay system for the detection of human platelet antigen 15 (HPA‐15) alloantibodies based on three techniques: an HPA‐15 expressing cell line, a monoclonal antibody‐specific antigen‐capture method and mixed‐passive haemagglutination

Contact Info

Product

Resources

About